E. Kokalaki

Affinity Gradient of Chimeric Antigen Receptor T-Cells Against Low-Antigen Density Target

E. Kokalaki, 2017 .

Tunable control of CAR T cell activity through tetracycline mediated disruption of protein–protein interaction

A. Piapi, G. Agliardi, S. Onuoha, 2021, Scientific Reports.

An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

K. Yong, S. Onuoha, M. Pule, 2018, Blood.

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

K. McHugh, I. Dragoni, A. Akarca, 2020, Science Translational Medicine.

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

T. Marafioti, S. Quezada, K. Peggs, 2014, Blood.

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2

M. Robson, M. Stavrou, A. Bulek, 2023, bioRxiv.

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

M. Robson, L. Stanczuk, S. Onuoha, 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

K. Yong, S. Onuoha, M. Pule, 2018, Blood.

Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors

Christopher Allen, M. Pule, E. Kokalaki, 2023, Cancer immunology research.

Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors

Christopher Allen, M. Pule, E. Kokalaki, 2023, bioRxiv.